According to the company, RGN-457 is based on thymosin beta 4 peptide formulated as an inhaled therapeutic agent to address the cystic fibrosis patient population.
JJ Finkelstein, RegeneRx’s president and CEO, said: “We have completed a substantial amount of preclinical work necessary for an investigational new drug application, in addition to existing toxicology and pharmacokinetic data from our current clinical programs.
“We believe RGN-457 could be developed relatively quickly with appropriate resources, thus, our interest is in identifying a strong strategic partner to work with us on this important product opportunity.”